18 May 2015

Feldene Gel (Piroxicam) - United Kingdom

ATC: M01AC
MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
OXICAMS
Feldene Gel

Generic Matches for Piroxicam (3)
Brexidol
Feldene capsules
FELDENE GEL

Last Updated on 18 May 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Feldene Gel Indication

Feldene Gel is a non-steroidal anti-inflammatory agent indicated for a variety of conditions characterised by pain and inflammation, or stiffness. It is effective in the treatment of osteoarthritis of superficial joints such as the knee, acute musculoskeletal injuries, periarthritis, epicondylitis, tendinitis, and tenosynovitis.

 

Feldene Gel Generic Name

Piroxicam

Type

POM

Summary Product Characteristics (SPCs) Links
SPC - Feldene Gel (external site)

Related Learning Zones

Bedwetting Knowledge Centre and CME

Bedwetting Knowledge Centre and CME

The Bedwetting Knowledge Centre, independently reviewed for clinical accuracy by Søren Rittig, MD, DMSc, aims to equip healthcare professionals with the information and guidance they need to effectively diagnose, treat and refer patients with nocturnal enuresis. This mobile-optimised resource contains disease awareness information, best practice guidelines and a CME activity ‘Case Studies in Urology: Best Practice Management of Bedwetting’.

Symptomatic Asthma Knowledge Centre and CME

Symptomatic Asthma Knowledge Centre and CME

Focusing on the lack of symptomatic control in patients with asthma, the new Symptomatic Asthma Learning Zone, consisting of a Disease Awareness section and an RCGP-accredited CME, is free to access for all epgonline.org members, and has been designed to provide them with the information they need to effectively manage the symptoms of their patients with asthma.

Feldene Gel Marketing Information

Feldene Gel Generic Name
Piroxicam
Marketing Company
Pfizer Limited
Drug Type
POM
Date of Issue, Marketing Authority 20/03/2009

Related Drugs - Rheumatology

Back to top